Clinical Trials Browser

Phase 1 × Active not recruiting × atezolizumab × Clear all

NCT06760481 2026-04-15

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Phase 1 Active not recruiting

Advanced Solid Malignancies

NCT06077500 2026-04-14

DAREONᵀᴹ-8

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Phase 1 Active not recruiting

SCLC,Extensive Stage

NCT04560972 2026-04-07

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

Phase 1 Active not recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

Melanoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT06537310 2026-03-03

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Cancer-Neoplasms

NCT04250155 2026-02-24

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Phase 1 Active not recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT04161755 2026-01-07

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03228537 2025-11-10

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase 1 Active not recruiting

28 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02862275 2025-10-23

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1 Active not recruiting

Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT05334329 2025-10-15

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04808245 2025-09-22

INTERCEPT-H3

Phase 1 Active not recruiting

Glioblastoma, Glioma

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04160494 2025-05-11

D2C7-IT With Atezolizumab for Recurrent Gliomas

Phase 1 Active not recruiting

Glioblastoma, Glioma

NCT03845166 2024-11-19

STELLAR-001

Phase 1 Active not recruiting

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT05022927 2024-09-05

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05878691 2024-07-22

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Phase 1 Active not recruiting

Lymphoma

NCT04134000 2024-05-21

BladderGATE

Phase 1 Active not recruiting

Urinary Bladder Neoplasms